Terug
Dagbereik
€ 20,94
€ 21,51
52-Weeksbereik
€ 13,40
€ 28,35
Volume
1.255.209
50D / 200D Gem.
€ 24,03
/
€ 23,75
Vorige Slotkoers
€ 20,74
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 9,2 | 0,4 |
| P/B | 2,9 | 2,9 |
| ROE % | 39,9 | 3,8 |
| Net Margin % | 36,5 | 3,9 |
| Rev Growth 5Y % | 22,0 | 10,0 |
| D/E | 0,0 | 0,2 |
Belangrijkste Punten
Revenue grew 21,97% annually over 5 years — strong growth
Earnings grew 72,66% over the past year
ROE of 39,89% indicates high profitability
Net margin of 36,49% shows strong profitability
Debt/Equity of 0,04 — conservative balance sheet
Generating 105,15M in free cash flow
Groei
Revenue Growth (5Y)
21,97%
Revenue (1Y)11,87%
Earnings (1Y)72,66%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
39,89%
ROIC6,14%
Net Margin36,49%
Op. Margin9,78%
Veiligheid
Debt / Equity
0,04
Current Ratio3,83
Interest Coverage0,00
Waardering
P/E Ratio
9,15
P/B Ratio2,92
EV/EBITDA32,95
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11,87% | Revenue Growth (3Y) | 21,45% |
| Earnings Growth (1Y) | 72,66% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 21,97% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,07B | Net Income (TTM) | 391,00M |
| ROE | 39,89% | ROA | 25,00% |
| Gross Margin | 91,69% | Operating Margin | 9,78% |
| Net Margin | 36,49% | Free Cash Flow (TTM) | 105,15M |
| ROIC | 6,14% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,04 | Current Ratio | 3,83 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 9,15 | P/B Ratio | 2,92 |
| P/S Ratio | 3,34 | PEG Ratio | 0,17 |
| EV/EBITDA | 32,95 | Dividend Yield | 0,00% |
| Market Cap | 3,58B | Enterprise Value | 3,45B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,07B | 957,80M | 726,44M | 517,24M | 484,15M |
| Net Income | 391,00M | 226,45M | -61,29M | -215,98M | -167,87M |
| EPS (Diluted) | 2,29 | 1,36 | -0,37 | -1,34 | -1,05 |
| Gross Profit | 982,51M | 875,96M | 680,71M | 507,07M | 465,00M |
| Operating Income | 104,81M | 230,79M | -73,38M | -223,60M | -170,44M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,56B | 1,19B | 748,96M | 587,81M | 700,12M |
| Total Liabilities | 336,81M | 454,96M | 317,20M | 187,40M | 159,23M |
| Shareholders' Equity | 1,23B | 732,79M | 431,76M | 400,41M | 540,89M |
| Total Debt | 52,19M | 52,00M | 57,21M | 62,00M | 64,43M |
| Cash & Equivalents | 177,70M | 319,59M | 188,66M | 114,85M | 147,44M |
| Current Assets | 1,06B | 938,32M | 616,13M | 507,94M | 617,82M |
| Current Liabilities | 277,11M | 394,87M | 254,25M | 125,63M | 96,07M |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt
Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt
Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt
Lower Risk
Mar 24, 2026